04/22/2026
A 12-week trial of acceptance and commitment therapy (ACT) using a smartphone app (Stanza) for fibromyalgia (FM) demonstrated large improvements in FM functional scores, pain intensity, pain interference, fatigue, and sleep disturbance in the ACT group with benefits emerging as early as 2–3 weeks into therapy. Engagement of study participants was high, and they rated the app as easy to use with minimal risk. The app is FDA approved and will soon become available in Florida by prescription only. These results support its use as a safe and effective tool for improving the quality of life and functioning of FM patients! Discuss this with your health care provider.